1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas

NMR in Biomedicine

Volumn 22, Issue 6, 2009, Pages 629-637

  Righi, Valeria ^a,b,c   Roda, Jose M ^d   Paz, José ^d   Mucci, Adele ^b   Tugnoli, Vitaliano ^c   Rodriguez Tarduchy, Gemma ^a   Barrios, Laura ^e   Schenetti, Luisa ^b   Cerdán, Sebastiían ^a   García Martín, María L ^a,f  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e CSIC Centro Tecnico de Informatica CTI   (Spain)

^f RM Nuestra Señora del Rosario ^*  (Spain)

Author keywords

Choline metabolism; Genomics; Gliomas; HR MAS; Tumors

Indexed keywords

CHOLINE KINASE; CHOLINE METABOLISM; DOMINANT CONTRIBUTIONS; DOWN-REGULATION; GENETIC BACKGROUNDS; GENOMIC ANALYSIS; GENOMICS; GLIOMAS; H NMR SPECTROSCOPY; HIGH RESOLUTION MAGIC ANGLE SPINNING; HIGH-GRADE GLIOMAS; HR-MAS; HUMAN TUMORS; IN-VIVO; LCMODEL; LOW GRADE; LOW-GRADE GLIOMAS; MAIN COMPONENT; PHOSPHOCHOLINE; PHOSPHOLIPASE A; PHOSPHOLIPASE C; PHOSPHOLIPASE D; RELATIVE CONTRIBUTION; RELATIVE QUANTIFICATION; UP-REGULATION;

BIOCHEMISTRY; BIOPSY; GENES; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; TUMORS;

METABOLISM;

CHOLINE; CHOLINE KINASE; CHOLINE KINASE BETA; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; GLYCEROPHOSPHORYLCHOLINE; LYSOPHOSPHOLIPASE; PHOSPHATIDATE PHOSPHATASE; PHOSPHOLIPASE A; PHOSPHOLIPASE A1; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; CANCER GRADING; COMPUTER PROGRAM; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; METABOLITE; PRIORITY JOURNAL; PROTON HIGH RESOLUTION MAGIC ANGLE SPINNING SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROSCOPY; TUMOR BIOPSY; UPREGULATION; BIOPSY; CHEMISTRY; GENETICS; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY;

ASTROCYTOMA; BIOPSY; CHOLINE; GLYCERYLPHOSPHORYLCHOLINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 70049104317     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1377     Document Type: Article

References (39)

1. Galanaud D, Chinot O, Metellus P, Cozzone P. [Magnetic resonance spectroscopy in gliomas] (in French). Bull. Cancer 2005; 92(4): 327-331.
2. Lafuente JV, Alkiza K, Garibi JM, Alvarez A, Bilbao J, Figols J, Cruz-Sanchez FF. Biologic parameters that correlate with the prognosis of human gliomas. Neuropathology 2000; 20(3): 176-183.
3. Narayana A, Chang J, Thakur S, Huang W, Karimi S, Hou B, Kowalski A, Perera G, Holodny A, Gutin PH. Use of MR spectroscopy and functional imaging in the treatment planning of gliomas. Br. J. Radiol. 2007; 80(953): 347-354.
4. Negendank WG, Sauter R, Brown TR, Evelhoch JL, Falini A, Gotsis ED, Heerschap A, Kamada K, Lee BC, Mengeot MM, Moser E, Padavic-Shaller KA, Sanders JA, Spraggins TA, Stillman AE, Terwey B, Vogl TJ, Wicklow K, Zimmerman RA. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J. Neurosurg. 1996; 84(3): 449-458.
5. Chen CY, Lirng JF, Chan WP, Fang CL. Proton magnetic resonance spectroscopy-guided biopsy for cerebral glial tumors. J. Formos. Med. Assoc. 2004; 103(6): 448-458.
6. McKnight TR, Lamborn KR, Love TD, Berger MS, Chang S, Dillon WP, Bollen A, Nelson SJ. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J. Neurosurg. 2007; 106(4): 660-666.
7. Yerli H, Agildere AM, Ozen O, Geyik E, Atalay B, Elhan AH. Evaluation of cerebral glioma grade by using normal side creatine as an internal reference in multi-voxel 1H-MR spectroscopy. Diagn. Interv. Radiol. 2007; 13(1): 3-9.
8. McKnight TR. Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism. Semin. Oncol. 2004; 31(5): 605-617.
9. Daly PF, Lyon RC, Faustino PJ, Cohen JS. Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. J. Biol. Chem. 1987; 262(31): 14875-14878.
10. Jeun SS, Kim MC, Kim BS, Lee JM, Chung ST, Oh CH, Lee SY, Choe BY. Assessment of malignancy in gliomas by 3T 1H MR spectroscopy. Clin. Imaging 2005; 29(1): 10-15.
11. Cheng LL, Chang IW, Louis DN, Gonzalez RG. Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res. 1998; 58(9): 1825-1832.
12. Tzika AA, Cheng LL, Goumnerova L, Madsen JR, Zurakowski D, Astrakas LG, Zarifi MK, Scott RM, Anthony DC, Gonzalez RG, Black PM. Biochemical characterization of pediatric brain tumors by using in vivo and ex vivo magnetic resonance spectroscopy. J. Neurosurg. 2002; 96(6): 1023-1031.
13. Martinez-Bisbal MC, Marti-Bonmati L, Piquer J, Revert A, Ferrer P, Llacer JL, Piotto M, Assemat O, Celda B. 1H and 13C HR-MAS spectroscopy of intact biopsy samples ex vivo and in vivo 1H MRS study of human high grade gliomas. NMR Biomed. 2004; 17(4): 191-205.
14. Valonen PK, Griffin JL, Lehtimaki KK, Liimatainen T, Nicholson JK, Grohn OH, Kauppinen RA. High-resolution magic-angle-spinning 1H NMR spectroscopy reveals different responses in choline-containing metabolites upon gene therapy-induced programmed cell death in rat brain glioma. NMR Biomed. 2005; 18(4): 252-259.
15. Tzika AA, Astrakas L, Cao H, Mintzopoulos D, Andronesi OC, Mindrinos M, Zhang J, Rahme LG, Blekas KD, Likas AC, Galatsanos NP, Carroll RS, Black PM. Combination of high-resolution magic angle spinning proton magnetic resonance spectroscopy and microscale genomics to type brain tumor biopsies. Int. J. Mol. Med. 2007; 20(2): 199-208.
16. Biernat W. 2000 World Health Organization classification of tumors of the nervous system. Pol. J. Pathol. 2000; 51(3): 107-114.
17. Pascual JM, Carceller F, Cerdán S, Roda JM. Diagnóstico diferencial de tumores cerebrales 'in vitro' por espectroscopía de resonancia magnética de protón. Método de los cocientes espectrales. Neurocirugía 1998; 9: 4-10.
18. Meiboom S, Gill D. Modified spin-echo method for measuring nuclear relaxation time. Rev. Sci. Instrum. 1958; 29: 688-691.
19. Aue WP, Bartholdi E, Ernst RR. Two-dimensional spectroscopy: application to nuclear magnetic resonance. J. Chem. Phys. 1976; 64: 2229-2246.
20. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993; 30(6): 672-679.
21. Agresti A. Categorical Data Analysis, 2nd (ed). John Wiley and Sons, Inc.: New York, 2002.
22. Tatsuoka M. Multivariate analysis. John Wiley & Sons, Inc.: New York, 1971.
23. Opstad KS, Bell BA, Griffiths JR, Howe FA. An investigation of human brain tumour lipids by high-resolution magic angle spinning (1)H MRS and histological analysis. NMR Biomed. 2008.
24. Kanowski M, Kaufmann J, Braun J, Bernarding J, Tempelmann C. Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn. Reson. Med. 2004; 51(5): 904-912.
25. Kim JH, Chang KH, Na DG, Song IC, Kwon BJ, Han MH, Kim K. 3T 1H-MR spectroscopy in grading of cerebral gliomas: comparison of short and intermediate echo time sequences. AJNR Am. J. Neuroradiol. 2006; 27(7): 1412-1418.
26. Martinez-Bisbal MC, Celda-Munoz B, Marti-Bonmati L, Ferrer-Ripolles P, Revert-Ventura AJ, Piquer-Belloch J, Molla-Olmos E, Arana-Fernandez de Moya E, Dosda-Munoz R. [The contribution of magnetic resonance spectroscopy to the classification of high grade gliomas. The predictive value of macromolecules]. Rev. Neurol. 2002; 34(4): 309-313.
27. Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Neurosurgery 1994; 35(4): 606-613; discussion 613-614.
28. Kinoshita Y, Yokota A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed. 1997; 10 2-12.
29. Peeling J. Sutherland G. High-resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn. Reson. Med. 1992; 24(1): 123-136.
30. Sabatier J, Gilard V, Malet-Martino M, Ranjeva JP, Terral C, Breil S, Delisle MB, Manelfe C, Tremoulet M, Berry I. Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. Invest. Radiol. 1999; 34(3): 230-235.
31. Usenius JP, Vainio P, Hernesniemi J, Kauppinen RA. Choline-containing compounds in human astrocytomas studied by 1H NMR spectroscopy in vivo and in vitro. J. Neurochem. 1994; 63(4): 1538-1543.
32. Griffin JL, Scott J, Nicholson JK. The influence of pharmacogenetics on fatty liver disease in the wistar and kyoto rats: a combined transcriptomic and metabonomic study. J. Proteome Res. 2007; 6(1): 54-61.
33. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59(1): 80-84.
34. Glunde K, Bhujwalla ZM. Choline kinase alpha in cancer prognosis and treatment. Lancet Oncol. 2007; 8(10): 855-857.
35. Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res. 2007; 67(23): 11284-11290.
36. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res. 1999; 59(13): 3112-3118.
37. Hiramatsu T, Sonoda H, Takanezawa Y, Morikawa R, Ishida M, Kasahara K, Sanai Y, Taguchi R, Aoki J, Arai H. Biochemical and molecular characterization of two phosphatidic acid-selective phospholipase A1s, mPA-PLA1alpha and mPA-PLA1beta. J. Biol. Chem. 2003; 278(49): 49438-49447.
38. Cummings BS. Phospholipase A2 as targets for anti-cancer drugs. Biochem. Pharmacol. 2007; 74(7): 949-959.
39. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004; 64(12): 4270-4276.